XPhyto Therapeutics Corp (CSE:XPHY) (OTCPINK:XPHYF) told investors Monday that development of its rapid saliva-based coronavirus (COVID-19) test is proceeding at an expedited basis at its diagnostic partner’s research lab in Germany.
Xphyto and 3a Diagnostics GmbH are developing a point-of-care lateral flow test to detect viral RNA in patent saliva, as well as from nasal and throat swabs, in fewer than five minutes.
3a’s enhanced RNA probe system has proven capable of detecting viral RNA in symptomatic, pre-symptomatic and asymptomatic patients alike, the company said.
The parties hope to win approval from European regulators in the first quarter of 2021, pending fast track certification from the German government, with commercial sales to follow soon after.
In addition to COVID-19, the lateral flow is capable of detecting the broader family of coronaviruses.
Prototype testing has confirmed successful activation of both the “COVID-19 specific probes” and the “universal coronavirus probes at viral RNA levels,” XPhyto noted in a statement.
The Vancouver-based company also announced that it is presenting at today’s Wall Street Reporter Next Super Stock Live virtual event at 12:30 pm ET.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel